BioNTech Investor Day Presentation Deck
Delivery formulations
A diversified and rationally designed delivery platform for mRNA medicine
Exploring novel delivery formulation through a
high-throughput screening platform to:
Optimize stability
Improve potency
Maintain immune quiescence/reduce immunogenicity
Seek PEG alternatives: reduce impact of anti-PEG
antibodies to improve pharmacokinetics
Seek alternative routes of administration
Polysarcosine-functionalized LNPs
exhibited comparable but
more durable in vivo expression
profile to pegylated LNPs
LNP, liquid nanoparticles; PEG, Polyethylene glycol.
Nogueira SS, et al. ACS Appl Nano Mater 2020; 3:10634-10645.
Plasma EPO [pg/ml]
1x107
1×106.
1×105.
1x104
1×103
1x102
1×101.
PSAR-LNP structure
PolySarcosine
PEG-
DMG
DODMA
DSPC
Cholesterol
RNA
HO
24 48
0 3 6
Time post intravenous injection [h]
-PBS
pSar23-DPL14
→PEG-DMG-DPL14
***
D
1
Multi-platform engine
LNP
BIONTECH
35View entire presentation